Related Experiment Video
Updated: Jul 17, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Small cell lung cancer (CPC). Second line treatment]
1Service de Pneumologie, Hôpital St-Antoine, Université Pierre et Marie Curie-Paris VI. bernard.lebeau@sat.ap-hop-paris.fr
Revue Des Maladies Respiratoires
|February 3, 2007
Summary
Most small cell lung cancers (SCLC) require second-line treatment due to resistance or relapse. Ongoing trials explore oral therapies and combinations to improve survival and quality of life for SCLC patients.
Area of Science:
- Oncology
- Medical Research
Context:
- Small cell lung cancer (SCLC) frequently recurs after initial treatment, necessitating further therapeutic strategies.
- A significant majority of SCLC patients require second-line treatment due to treatment failure, progression, or relapse.
Purpose:
- To review the current landscape of second-line treatment options for small cell lung cancer (SCLC).
- To highlight ongoing research focused on improving treatment efficacy and patient quality of life in recurrent SCLC.
Summary:
- Second-line treatment for SCLC yields response rates of 70% for relapsed cases (after complete response) and 20-30% for refractory cases.
- Current research investigates novel oral treatments and combination therapies, such as lomustine, cyclophosphamide, and etoposide, to enhance survival and comfort.
Impact:
- Establishes the critical need for effective second-line treatments in SCLC management.
- Suggests that novel therapeutic approaches, including oral agents and combination regimens, hold promise for improving outcomes in SCLC patients.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...